The DOI matches its Crossref record; 51 of the 54 references it cites were found in a registry or an index; 21 of the 28 sources its claims cite were checked for support.
Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C -mutant Colorectal Cancer
Open accessPublished version of a preprint
Abstract
Novel covalent inhibitors of KRASG12C have shown limited response rates in patients with KRASG12C-mutant (MT) colorectal cancer. Thus, novel KRASG12C inhibitor combination strategies that can achieve deep and durable responses are needed. Small-molecule KRASG12C inhibitors AZ’1569 and AZ’8037 were used. To identify novel candidate combination strategies for AZ’1569, we performed RNA sequencing, siRNA, and high-throughput drug screening. Top hits were validated in a panel of KRASG12CMT colorectal cancer cells and in vivo. AZ’1569-resistant colorectal cancer cells were generated and characterized. We found that response to AZ’1569 was heterogeneous across the KRASG12CMT models. AZ’1569 was ineffective at inducing apoptosis when used as a single agent or combined with chemotherapy or agents targeting the EGFR/KRAS/AKT axis. Using a systems biology approach, we identified the antiapoptotic BH3-family member BCL2L1/Bcl-xL as a top hit mediating resistance to AZ’1569. Further analyses identified acute increases in the proapoptotic protein BIM following AZ’1569 treatment. ABT-263 (navitoclax), a pharmacologic Bcl-2 family inhibitor that blocks the ability of Bcl-xL to bind and inhibit BIM, led to dramatic and universal apoptosis when combined with AZ’1569. Furthermore, this combination also resulted in dramatically attenuated tumor growth in KRASG12CMT xenografts. Finally, AZ’1569-resistant cells showed amplification of KRASG12C, EphA2/c-MET activation, increased proinflammatory chemokine profile and cross-resistance to several targeted agents. Importantly, KRAS amplification and AZ’1569 resistance were reversible upon drug withdrawal, arguing strongly for the use of drug holidays in the case of KRAS amplification. Taken together, combinatorial targeting of Bcl-xL and KRASG12C is highly effective, suggesting a novel therapeutic strategy for patients with KRASG12CMT colorectal cancer.
Overview
CoChat Summary
TL;DR
In KRASG12C-mutant colorectal cancer, KRASG12C inhibition alone poorly induces apoptosis, but Bcl-xL blockade releases BIM and produces robust apoptosis when combined with KRASG12C inhibition. Acquired AZ’1569 resistance in this model is driven by KRAS amplification, bypass RTK activation, and a proinflammatory phenotype, and is reversible after drug withdrawal.
Key findings
- AZ’1569 response was heterogeneous across 7 KRASG12C-mutant colorectal cancer cell lines: IC50 values were 0.26 and 0.43 μmol/L in RW7213 and C106, 1.39, 1.54, and 1.72 μmol/L in SW1463, SW837, and LIM2099, and 2.96 and 3.4 μmol/L in SNU1411 and V481; only RW7213 and C106 showed marked apoptosis after AZ’1569.
- A 42-target siRNA screen identified BCL2L1/Bcl-xL as the only significant hit sensitizing both SW837 and SNU1411 cells to AZ’1569; Bcl-xL/BAK ratio correlated with AZ’1569 response (r = 0.54), and AZ’1569 acutely increased BIM, which navitoclax/ABT-263 disrupted from Bcl-xL complexes.
- ABT-737 combined with AZ’1569 was synergistic and induced apoptosis across the KRASG12C-mutant panel; in vivo, navitoclax plus AZ’8037 caused marked tumor shrinkage in SW1463 xenografts and further growth reduction without regression in SNU1411 xenografts.
- Three AZ’1569-resistant RW7213 clones showed KRAS amplification, elevated KRAS-GTP/mRNA and pERK1/2, c-MET/EphA2 activation, cross-resistance to sotorasib, adagrasib, chemotherapy, and several targeted agents; resistance reversed after 8 weeks of AZ’1569 withdrawal, and resistant clones showed >300-fold increased CD274/PD-L1 and increased IL8, CXCL1, IFNγ, and TGFα.
Methods
- In vitro studies used 7 KRASG12C-mutant colorectal cancer cell lines plus HCT116, with Sanger sequencing, cell viability assays, caspase-3/7 assays, Western blotting, immunoprecipitation, RT-PCR, cytokine/RTK arrays, ELISAs, RAS-GTP assays, RNA-seq, a 42-target siRNA screen, and a 45-compound drug screen.
- In vivo efficacy used NOD SCID mice bearing SNU1411 or SW1463 xenografts; mice received vehicle, AZ’8037 (100 mg/kg orally daily), navitoclax (100 mg/kg orally 5 of 6 days), or the combination, with eight animals per group.
- Analyses included robust z-scores, Chou-Talalay combination index/RI values, GraphPad statistics, and MedExome/NGS for resistant clones.
Limitations
- Stated in the paper: further biomarker analysis of patient tissue is needed to confirm the predictive role of BIM; the navitoclax/AZ’8037 combination was less well tolerated in the SNU1411 model; and SNU1411 xenografts showed no tumor regression with the combination.
- Evident from the text: the main findings are preclinical, based on a small panel of 7 KRASG12C-mutant colorectal cancer cell lines and two xenograft models, with acquired resistance generated from a single sensitive cell line (RW7213) and three resistant clones.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
14 Valid · 2 Not valid · 4 Not checked · 105 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“combination treatments with navitoclax have been widely trialed in other in vivo strains and patients without major reported toxicities”
§ Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer > Discussion
What the sources say
- Partly supportedcites [46] Corcoran, 2013, Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models, Cancer Cell sourceExperimental — accuracy not yet measured
The Results (page not available) report that mice receiving navitoclax plus selumetinib showed no overt signs of toxicity across three KRAS-mutant xenograft models. The paper does not establish that navitoclax combinations were widely trialed in other in vivo strains or in patients without major reported toxicities; it instead proposes clinical evaluation. (LLM, conf=0.88)
- Disputedcites [49] Corcoran, 2019, Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours, Ann Oncol sourceExperimental — accuracy not yet measured
The Results report grade 3–4 treatment-related adverse events in 40% of the 43 patients, contrary to the claim that no major toxicities were reported. The paper describes a navitoclax–trametinib trial in patients and mentions tumour regressions in mouse models, but does not establish that navitoclax combinations were widely trialed across other strains and patients. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“an effective therapeutic strategy for KRASMT colorectal cancer, the most common genetically defined subtype (∼40%–45%) is still lacking.”
§ Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer > Introduction
What the sources say
- Disputedcites [6] Kubicka, 2013, Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings, Ann Oncol sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says KRAS mutations occur in about 40% of patients with metastatic colorectal cancer, consistent with the prevalence in the claim. But the Results (patient population; page unavailable) report significantly prolonged progression-free survival with bevacizumab plus chemotherapy in patients with KRAS-mutant tumors, contrary to the assertion that an effective therapeutic strategy is lacking. Overall survival was not significantly improved in that subgroup. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Novel covalent inhibitors of KRASG12C have shown limited response rates in patients with KRASG12C-mutant (MT) colorectal cancer.”
§ Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer > Abstract
What the sources say
- Supportedcites [10] Hong, 2020, KRAS(G12C) inhibition with sotorasib in advanced solid tumors, N Engl J Med source
The Results > Efficacy section reports a confirmed partial response in 3 of 42 patients (7.1%) with colorectal cancer treated with the KRASG12C inhibitor sotorasib. This supports the claim that response rates were limited in this patient group. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although recent clinical trials of KRASG12C inhibition have shown modest efficacy in KRASG12CMT colorectal cancer”
§ Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer > Results > Generation of colorectal cancer models with acquired resistance to KRASG12C inhibition
What the sources say
- Supportedcites [28] Awad, 2021, Acquired resistance to KRAS(G12C) inhibition in cancer, N Engl J Med source
The introductory passage following the Abstract’s Conclusions states that early-phase trials of adagrasib and sotorasib showed more modest efficacy in colorectal cancer than in NSCLC, and gives colorectal-cancer response rates of 17% and 7.1%. The Discussion also refers to the more modest activity of KRASG12C inhibitors in colorectal cancer. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“emergence of acquired resistance limits further clinical benefit (28)”
§ Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer > Results > Generation of colorectal cancer models with acquired resistance to KRASG12C inhibition
What the sources say
- Supportedcites [28] Awad, 2021, Acquired resistance to KRAS(G12C) inhibition in cancer, N Engl J Med source
The introductory text following the Abstract Conclusions states that acquired resistance to single-agent KRASG12C inhibitors eventually occurred in most patients despite clinical benefit. The Abstract Results include patients with colorectal cancer, and the Discussion describes acquired resistance mechanisms in the treated cohort. The paper does not establish that resistance explains the more modest initial efficacy in colorectal cancer, but the cited claim does not require that conclusion. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
86 more claims · 4 with their cited sources checked
Create a free account to see all 125 claims and every source verdict.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 25
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Feedback activation of EGFR, c-MET, and EphA2 was also found in cell lines resistant to another KRAS inhibitor, AZ1569 [75].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [75]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which could be overcame by co-targeting Bcl-XL using ABT-263 [75].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [75]
The cited source says what the claim attributes to it.
In the citing paper
“Bcl-XL, an antiapoptotic Bcl-2 family member, was found to mediate resistance of CRC cells to the KRAS G12C inhibitor AZ’1569”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer > Results > KRASG12C inhibition does not sensitize KRASG12CMT colorectal cancer cells to chemotherapy
“Although combined cetuximab/AZ’1569 treatment resulted in major reduction in cell viability (Supplementary Fig. S1G), efficient apoptosis induction occurred only in RW7213 and C106 cells (Fig. 2D).”
§ Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer > Discussion
“However, addition of cetuximab to AZ’1569 only resulted in potent increases in cell death in three of seven KRASG12CMT colorectal cancer models.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer > Results > KRAS G12CMT colorectal cancer xenograft models are sensitive to combinatorial Bcl-xL/KRASG12C inhibition
“The navitoclax/AZ’8037 combination was less well tolerated in this second mouse model as shown by decreases in tumor weight in week 2 of the treatment (Fig. 5B).”
§ Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer > Results > KRAS G12CMT colorectal cancer xenograft models are sensitive to combinatorial Bcl-xL/KRASG12C inhibition
“B, Growth rate (left) and mouse weight (right) of SNU1411 xenografts in NOD/SCID mice treated with vehicle, AZ’8037, navitoclax, or AZ’8037 in combination with navitoclax.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer > Results > BCL2L1 is a key regulator of apoptotic response to KRASG12C inhibition in KRASG12CMT colorectal cancer cells
“Immunoprecipitation of BIM confirmed that BIM levels were induced by AZ’1569, and the BH3-mimetic ABT-263 (navitoclax) completely disrupted the association of Bcl-xL with BIM under basal conditions and following BIM induction by AZ’1569 (Supplementary Fig. S3D).”
§ Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer > Discussion
“Consistent with previous studies, we showed that ABT-737 abrogates the inhibitory complex between Bcl-xL and BIM (Supplementary Fig. S3D; ref. 44)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer > Results > KRASG12C inhibition does not sensitize KRASG12CMT colorectal cancer cells to chemotherapy
“CI values for combined AZ’1569/5-FU treatment were >0.7 for the majority of the concentrations, indicative of additive interactions (Fig. 2A).”
§ Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer > Materials and Methods > Statistical analysis
“CI values <1, >1, and = 1 indicate synergy, antagonism, and additive effects, respectively.”
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 2×
“The nature of interaction between AZ’1569 and a second drug was determined by calculating combination index (CI) values according to the Chou-Talalay method (18), using CalcuSyn (Microsoft Windows).”
MethodThe consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“Thus, the genetic background of these models captures some of the heterogeneity of KRASMT colorectal cancer observed in tumors (24).”
BackgroundK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“Recently, unique characteristics of the KRAS allele have been exploited for the design of a number of covalent inhibitors that bind specifically to the cysteine at position 12, thereby locking KRAS in its inactive state (7).”
BackgroundThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 2×
“Recently, drugs such as sotorasib and adagrasib, which inhibit KRAS, have emerged as promising targeted therapies for patients with KRASMT lung cancer (32, 33).”
BackgroundDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 10×
“org Mol Cancer Ther; 22(1) January 2023 143”
BackgroundInfluentialRAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 5×
“Raw values were normalised to ACTB and GAPDH expression and were analysed using the ΔΔCT method.”
BackgroundInfluentialKRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · cited 1×
“Although substantial advances have been made in the treatment of genetically defined subtypes, such as RAS/BRAF wild-type (4) and BRAFMT colorectal cancer (5), an effective therapeutic strategy for KRASMT colorectal cancer, the most common genetically defined subtype ( 40%–45%) is still lacking.”
BackgroundHallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · cited 2×
“Recently, drugs such as sotorasib and adagrasib, which inhibit KRAS, have emerged as promising targeted therapies for patients with KRASMT lung cancer (32, 33).”
BackgroundResultAcquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Cited by
Biological insights in non-small cell lung cancer
Rosell, R., Jain, A. S., Codony‐Servat, J., Lewintre, E. J., Morrison, B., Barretina, J., & González‐Cao, M. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0108 · Cited by 63
Żyła, J., Papież, A., Zhao, J., Qu, R., Li, X., Kluger, Y., Polańska, J., Hatzis, C., Pusztai, L., & Marczyk, M. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.09.035 · Cited by 17
“…all factors with 95% CI for the mean (calculated from all samples within the study). specific for the bulk RNA-Seq data included different cancer pathways where navitoclax is used for treatment: Acute myeloid leukemia [40], Colorectal cancer [41], and Human T-cell leukemia virus 1 infection [42].”
MethodPallathadka, H., Hsu, C., Saleh, R. O., Jyothi, S. R., Kumar, A., Yumashev, A., Sinha, A., Zwamel, A. H., Jawad, M. A., & Alsaadi, S. B. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112730 · Cited by 13
A Pegylated Liposome Loaded with Raddeanin A for Prostate Cancer Therapy
He, K., Wang, T., Chen, J., Huang, X., Wang, Z., Yang, Z., Wang, K., Zhao, W., Jiang, J., & Zhao, L. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s420803 · Cited by 7
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
“Feedback activation of EGFR, c ‐ MET, and EphA2 was also found in cell lines resistant to another KRAS inhibitor, AZ1569 [77].”
Metadata
- Authors
- Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., Lambe, S., Maurya, M., Lindner, A. U., Prehn, J. H. M., Sousa, J., Winnington, C., LaBonte, M. J., Ross, S., & Van Schaeybroeck, S.
- Affiliations
- Queen's University Belfast (GB)
- AstraZeneca (United Kingdom) (GB)
- Candiolo Cancer Institute (IT)
- 3Department of Oncology, University of Torino, Candiolo, Torino, Italy.
- Royal College of Surgeons in Ireland (IE)
- 1Drug Resistance Group, Patrick G. Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, United Kingdom.
- ORCID
- Khawaja, Hajrah
- Briggs, Rebecca
- Latimer, Cheryl H.
- Rassel, Mustasin
- Griffin, Daryl
- Hanson, Lyndsey
- Bardelli, Alberto
- Di Nicolantonio, Frederica
- McDade, Simon S.
- Scott, Christopher J.
- Lambe, Shauna
- Maurya, Manisha
- Lindner, Andreas U.
- Prehn, Jochen H.M.
- Sousa, Jose
- Winnington, Chris
- LaBonte, Melissa J.
- Ross, Sarah
- Van Schaeybroeck, Sandra
- Venue
- Molecular Cancer Therapeutics
- Published
- 2022-10-22
- Volume
- 22
- Issue
- 1
- Pages
- 135-149
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- PMC
- PMC9808374
- OpenAlex
- W4307187376
- Semantic Scholar
- 71523d32b56dd0e5cdbad0099d7534cb5aaa3a7b
- Cited by
- 12
- References
- 54
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 2 · 2023: 3
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Cancer Therapeutics (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (publishedVersion, cc-by)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Figshare (submittedVersion, cc-by)
- Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
- Funders
- Cancer Research UK (C212/A7402)
- European Commission (602901)
- Science Foundation Ireland (16/US/3301)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- KRAS G12C, colorectal cancer, Bcl-xL, apoptosis, building information modeling, navitoclax, drug resistance, KRAS amplification, EphA2, c-Met, drug holidays, combination therapy
- MeSH terms
- Antineoplastic Agents, Humans, Proto-Oncogene Proteins, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Apoptosis, Proto-Oncogene Proteins c-bcl-2, Cell Line, Tumor, bcl-X Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C -mutant Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-22-0301
- The paper
- Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., Lambe, S., Maurya, M., Lindner, A. U., Prehn, J. H. M., Sousa, J., Winnington, C., LaBonte, M. J., Ross, S., & Van Schaeybroeck, S. (2023). Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C -mutant Colorectal Cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-22-0301
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.